Bethany Hills joins DLA Piper’s FDA Regulatory practice in New York

DLA Piper continues the growth of its FDA Regulatory group with the arrival of Bethany Hills as a partner in the firm’s New York office. Hills will join as vice chair of the FDA practice, working with co-chairs Geoff Levitt and Stefanie Fogel to support their rapid expansion of DLA Piper’s FDA regulatory capabilities.

Hills advises life sciences and health tech industry clients on both pre- and post-market issues, with clients spanning the full range of FDA and healthcare regulated companies, including medical device and health tech, drug, combination product, diagnostic, biologic, and regenerative medicine, cosmetic, dietary supplement, and food industry businesses. She also counsels the investor groups focusing on innovation in these industries.

In addition, Hills helps companies manage FDA regulation issues, from product development and classification, to inspections and investigations, through complex regulatory challenges, including product approvals and labeling to collaborative research, supply and distribution agreements.

“Expanding our FDA Regulatory group is one of DLA Piper’s top priorities, and Bethany’s arrival is a critical strategic part of that effort,” said Edward “Smitty” Smith, chair of the firm’s Regulatory and Government Affairs practice. “Her FDA regulatory experience and exceptional knowledge of the healthcare delivery system is a true asset to our clients as they navigate this evolving industry.”

Hills’ arrival is the latest in a series of additions to the group. This year, Melissa Gilmore (Washington, DC), Jarred Reiling (New York) and Keo Shaw (San Francisco) have joined the firm as counsel. “This is just the start,” said Smith. “We will build an FDA Regulatory group that is second to none.”

About DLA Piper’s FDA Regulatory Team

DLA Piper’s FDA Regulatory practice provides strategic counselling and advocacy for pharmaceutical, medical device, dietary supplements, food and beverage, biologics, cannabis, tobacco and diagnostics and clinical laboratory companies in a wide range of matters involving the FDA and other government agencies, from clinical development and marketing authorization strategies to post-marketing compliance. Our attorneys combine an understanding of agency practice, science, policy, and bioethics with practical strategies to meet business objectives and mitigate risk in an increasingly complex regulatory and enforcement environment.